This trial is looking at how well zanzalintinib works compared to everolimus. Both medicines are for people with advanced neuroendocrine tumors that cannot be removed by surgery. These tumors can start in the pancreas or other places in the body. The goal is to see which medicine helps keep the cancer under control better.
This is a Phase 2/3 trial, which means it is looking at how well the treatments work and how safe they are. The trial is regulated by the FDA and plans to include about 440 participants.
Who can join
Adults aged 18 and older can participate. This study is open to all men and women. Participants must have certain types of neuroendocrine tumors that are advanced and cannot be treated with surgery. Some people may not be able to join if they have certain other types of cancer or have had certain treatments recently. The trial team will confirm who is eligible to join.
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into two groups. One group will take zanzalintinib tablets once daily. The other group will take everolimus tablets once daily. Everyone will receive one of these two treatments as part of the study.
Where
This trial is enrolling at 39 locations. Recruiting sites are listed first.
Treats pancreatic cancer, lung cancer and colorectal cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Led global trials in liver and bile duct cancer. Treats pancreatic cancer, gallbladder cancer, bile duct cancer and liver cancer. Offers targeted therapy.
Directs genitourinary oncology at Huntsman Cancer Institute. Treats pancreatic cancer, liver cancer, gallbladder cancer and esophageal cancer. Also treats stomach cancer and colorectal cancer.